Biovicosp. z o.o.

Manufacture of medical and dental instruments and supplies

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2008-12-11
Share capital
1 066 500,00 PLN
Activity description

Biovico is a biotechnology and pharmaceutical company focused on researching and developing rigorously tested healthcare products. They specialize in advancements in biologics and pharmaceuticals aimed at enhancing patient health and well-being globally.

Registered address
ul. Hutnicza 15B, 81-061 Gdynia, Poland
Website
biovico.comWebsite active
Email
Email address current
Phone
Social media

Financials

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 32.72mMedianUSD 252.87kAverageUSD 4.60m
Net profit
This companyUSD 11.02mMedianUSD 8.64kAverageUSD 200.73k
Operating costs
This companyUSD 21.86mMedianUSD 267.10kAverageUSD 4.21m
Assets
This companyUSD 30.43mMedianUSD 228.68kAverageUSD 5.40m

Bank accounts

Registered as a VAT taxpayer on 2008-12-20. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Real estate

TypeAmount
Land (incl. perpetual usufruct)
$2.0M
Buildings and premises
$6.1M

MSiG notices

Publication dateEvent
Jan 14, 2026Commercial Companies Code notice

Public aid

40 public aid cases recorded, with a total value of $7,803,881.

PurposeGross amount
Aid for research and development projects: experimental development
–
Aid for research and development projects: industrial research
–
Aid for participation in trade fairs for small and medium-sized enterprises
–

European Funds

11 projects recorded: 10 from FE lists ($8,140,785) and 1 Commission grant (FTS) ($119,208).

ProjectEU co-financing
Rozwój i wdrożenie hybrydowej matrycy o wysokim potencjale chondrogennym wykorzystywanej podczas jednoetapowej procedury naprawy ubytków chrząstki stawowej
$1.8M
Ocena bezpieczeństwa i skuteczności działania innowacyjnego produktu opartego o polimer syntetyczny, stosowanego do wiskosuplementacji stawów.
$262.5K
Opracowanie i wdrożenie innowacyjnego produktu na bazie sieciowanego kwasu hialuronowego z wartością dodaną stosowany jako skuteczna bariera antyadhezyjna.
$1.1M

Tenders

103 tenders recorded as contractor: 44 national ($1,870,890) and 59 EU ($83,984,855).

SubjectAmount
„Dostawy implantów i materiałów zużywalnych dla potrzeb Kliniki Chirurgii Ortopedyczno-Urazowej Wojewódzkiego Szpitala Zespolonego w Kielcach”
$131.8K
Dostawa materiałów jednorazowego użytku ( obłożenia , zestawy, implanty ortopedyczne, membrany, akcesoria i narzędzia do zabiegów urologicznych i ortopedycznych) używanych na salach operacyjnych w 26 Pakietach
$250.8K
Dostawy endoprotez oraz innych implantów ortopedycznych
$486.8K

Public sector contracts

Biovico is the contractor in 17 public sector contracts, worth PLN 25.56k in total. They were signed with 2 public buyers. The largest number (15) were signed with Zespół Opieki Zdrowotnej w Strzyżowie.

Public buyerValue
Zespół Opieki Zdrowotnej w StrzyżowiePLN 1,245
Zespół Opieki Zdrowotnej w StrzyżowiePLN 1,195
Zespół Opieki Zdrowotnej w StrzyżowiePLN 1,245
Zespół Opieki Zdrowotnej w StrzyżowiePLN 1,175
Zespół Opieki Zdrowotnej w StrzyżowiePLN 740.00

Trademarks

Biovico holds 18 active trademarks registered with the Polish Patent Office. 20 marks have expired or were not registered. The first mark was filed in 2009.

MarkProtected until
CEBEDEFIX(word)Jul 20, 2030
lipotris(word)May 27, 2030
Wilandt Pharma(word)Aug 17, 2028
HALEVOX(word)Aug 17, 2028
TIRECO(word)May 27, 2028

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Authorized Representatives

Aleksandra Taraszkiewicz Maryjanowska – Management Board Member
Anna Barbara Łuba – Management Board Member
Norbert Wilandt – President of the Management Board

Manner of representation

In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.

Ownership

OwnerSharesShare valueStake
Wilandt Brothers S.A.
1,941$262,155.5990.9986%
Others
192$25,931.939.0014%

Beneficial owners

Person

Competitors

Name
MargomedS.A.

Change history

DateEvent
2025-03-03Name change
2022-03-04PKD change
2020-08-03PKD change
2018-09-11Address change
2016-11-04PKD change

FAQ

Last updated: 2026-10-07